A COVID-19 vaccine being developed by AstraZeneca and Oxford University produced a strong immune response in older adults, data published on Thursday showed.

The data, published Thursday in The Lancet medical journal, shed more light on preliminary data released in recent months showing the experimental shot generated a strong immune response in people over age 70, who are at highest risk of severe illness.

Dr. Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said Thursday that scientists expect to report full results from the late-stage trials of their COVID-19 vaccine by Christmas.

“I think we’re getting close, and it’s definitely going to be before Christmas based on the progress,” Dr. Pollard told the BBC.

Advertise with us

Dr. Pollard discussed progress in the late-stage trials as Oxford released a study based on earlier research that found the vaccine was well tolerated among older adults. He said this is important because vaccines often don’t work as well in older people. The recent findings were based on a so-called phase II trial of 560 people, including 240 over the age of 70.

The Oxford-AstraZeneca COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or SARS-CoV-2.

The past two weeks have brought a flurry of promising vaccine news. Pfizer, working with Germany’s BioNTech SE, said Wednesday that its shot was 95% effective in a final analysis of trial data, paving the way for the company to apply for U.S. regulatory clearance. Moderna also this week announced results showing its vaccine is equally effective.

Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), AstraZeneca’s is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees.

Dr. Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal.

Advertise with us

Despite recent progress, Dr. Pollard said the world is still in the early stages of the effort to protect people against COVID-19. Even after vaccines are approved by regulators, drugmakers and public health officials still face the task of producing billions of doses and administering them to people around the world, he said.

An amateur mountaineer, Dr. Pollard compared the task to the work involved in climbing a mountain.

“I think we’re still at the bottom of that mountain in some ways,” he said. “We’ve done the route into the bottom of the mountain, the long trek to get to the start. Now we’ve got to get the data about the vaccines in front of regulators for them to scrutinize it and approve the first vaccines. And then we’ve got that huge effort to climb up to the top where we’ve got a vast majority of those who are at risk vaccinated.”

This story will be updated.

Bloomberg News contributed.